2025年中国批准上市多款创新药 30款已纳入医保
Jing Ji Guan Cha Wang·2026-01-20 05:35
Core Insights - The National Medical Products Administration approved 76 innovative drugs for market entry in 2025, marking a record high and showcasing a trend of diversified innovative therapies accelerating in China [1] - Among the 43 new drugs approved for inclusion in the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog from January 1 to June 30, 2025, 30 successfully entered the national insurance catalog through negotiations [1] - The coverage rate of new drugs approved in the first half of 2025 for the national insurance catalog is expected to reach 70%, with these drugs eligible for reimbursement starting January 1, 2026, thereby reducing the financial burden on patients [1]